TFX vs. RMD, STE, HOLX, BAX, PODD, GMED, MASI, ITGR, IART, and ATEC
Should you be buying Teleflex stock or one of its competitors? The main competitors of Teleflex include ResMed (RMD), STERIS (STE), Hologic (HOLX), Baxter International (BAX), Insulet (PODD), Globus Medical (GMED), Masimo (MASI), Integer (ITGR), Integra LifeSciences (IART), and Alphatec (ATEC). These companies are all part of the "health care equipment" industry.
ResMed (NYSE:RMD) and Teleflex (NYSE:TFX) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, community ranking, profitability, earnings, institutional ownership and risk.
ResMed has a net margin of 20.91% compared to ResMed's net margin of 9.82%. Teleflex's return on equity of 24.43% beat ResMed's return on equity.
ResMed pays an annual dividend of $1.92 per share and has a dividend yield of 0.9%. Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.6%. ResMed pays out 29.5% of its earnings in the form of a dividend. Teleflex pays out 21.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
ResMed has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
In the previous week, Teleflex had 5 more articles in the media than ResMed. MarketBeat recorded 10 mentions for Teleflex and 5 mentions for ResMed. Teleflex's average media sentiment score of 1.67 beat ResMed's score of 1.15 indicating that ResMed is being referred to more favorably in the media.
ResMed has higher revenue and earnings than Teleflex. ResMed is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.
ResMed currently has a consensus target price of $202.80, indicating a potential downside of 3.85%. Teleflex has a consensus target price of $257.29, indicating a potential upside of 21.04%. Given ResMed's higher probable upside, analysts plainly believe Teleflex is more favorable than ResMed.
Teleflex received 103 more outperform votes than ResMed when rated by MarketBeat users. Likewise, 59.54% of users gave Teleflex an outperform vote while only 52.93% of users gave ResMed an outperform vote.
55.0% of ResMed shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 1.2% of ResMed shares are held by company insiders. Comparatively, 1.4% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
ResMed beats Teleflex on 11 of the 20 factors compared between the two stocks.
Get Teleflex News Delivered to You Automatically
Sign up to receive the latest news and ratings for TFX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teleflex Competitors List
Related Companies and Tools
